Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$19.74
+0.1%		$24.47
$18.39
▼
$30.96
$3.40B0.881.98 million shs1.23 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$245.15
+0.7%		$242.53
$188.07
▼
$282.15
$15.18B0.38753,932 shs545,004 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%+3.19%-4.59%-22.29%-10.40%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+8.04%+7.88%-3.97%+20.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$19.74
+0.1%		$24.47
$18.39
▼
$30.96
$3.40B0.881.98 million shs1.23 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$245.15
+0.7%		$242.53
$188.07
▼
$282.15
$15.18B0.38753,932 shs545,004 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%+3.19%-4.59%-22.29%-10.40%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+8.04%+7.88%-3.97%+20.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.72
Moderate Buy$31.3458.77% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.95
Moderate Buy$305.9524.80% Upside

Current Analyst Ratings Breakdown

Latest ACAD and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/26/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$268.00
10/26/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$360.00 ➝ $330.00
10/19/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$35.00
10/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$307.00 ➝ $269.00
10/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold (C)
10/13/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Neutral$49.00 ➝ $23.00
10/8/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$37.00 ➝ $36.00
9/28/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
William Blair logo
William Blair
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$33.00
9/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$38.00 ➝ $31.00
9/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$41.00 ➝ $35.00
9/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$40.00 ➝ $33.00
(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B3.17$0.89 per share22.24$7.25 per share2.72
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.77N/AN/A($2.97) per share-82.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.228.8920.14N/A33.42%9.03%6.79%11/4/2026 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8919.0227.54N/A70.99%32.54%7.71%11/11/2026 (Estimated)

Latest ACAD and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.9130N/AN/AN/A$412.08 millionN/A
11/4/2026Q3 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.1992N/AN/AN/A$332.58 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.31 million127.16 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable

Recent News About These Companies

Ascendis Pharma A/S announces TransCon PTH pooled data showing kidney function improvements for up to 5 years
 |  msn.comhttps://www.msn.com/en-us/health/general/ascendis-pharma-a-s-announces-transcon-pth-pooled-data-showing-kidney-function-improvements-for-up-to-5-years/ar-AA2g73a3
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
October 26 at 3:07 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/transcon-pth-palopegteriparatide-demonstrates-sustained-clinically-meaningful-improvements-in-kidney-function-in-adults-with-hypoparathyroidism-treated-up-to-5-years-1036665250
Ascendis Pharma Says Trial Results Show 'Meaningful Improvements' in Kidney Function in Adults with Hypoparathyroidism
October 26 at 3:07 PM  |  marketscreener.comM
Ascendis Pharma A/S $ASND Shares Newly Bought by Inspire Investing LLC
October 26 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ascendis-pharma-as-asnd-shares-newly-bought-by-inspire-investing-llc-2026-10-26/
Ascendis Pharma A/S $ASND Shares Purchased by Assenagon Asset Management S.A.
October 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ascendis-pharma-as-asnd-shares-purchased-by-assenagon-asset-management-sa-2026-10-21/
Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141359
Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26 According to Analysts
October 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ascendis-pharma-as-nasdaq-asnd-stock-has-consensus-price-target-of-30926-according-to-analysts-2026-10-21/
Ascendis Pharma A/S (NASDAQ:ASND) & Generate Biomedicines (NASDAQ:GENB) Head-To-Head Survey
October 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31132260
Ascendis Pharma A/S Receives Positive CHMP Opinion Recommending Marketing Authorization For Once-Weekly TransCon CNP For The Treatment Of Achondroplasia In Children
October 17, 2026  |  marketscreener.comM
ASND shares shrug off positive European opinion for FDA-approved achondroplasia drug
October 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug/ar-AA2epn2U
Ascendis Pharma (ASND) Receives a New Rating from a Top Analyst
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/7974211/ascendis-pharma-asnd-receives-a-new-rating-from-a-top-analyst/
Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia
October 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ascendis-pharma-apos-transcon-cnp-125804760.html
Ascendis Pharma Receives Positive CHMP Opinion for EU Marketing Authorization of Once-Weekly TransCon CNP for Achondroplasia
October 16, 2026  |  quiverquant.comQ
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
October 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/16/3382571/0/en/once-weekly-transcon-cnp-navepegritide-receives-positive-chmp-opinion-for-the-treatment-of-achondroplasia-in-children.html
RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ASND/pressreleases/5521392/rbc-capital-sticks-to-its-buy-rating-for-ascendis-pharma-asnd/
Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ASND/pressreleases/4898426/barclays-reaffirms-their-buy-rating-on-ascendis-pharma-asnd/
UBS Adjusts Ascendis Pharma A/S Price Target to $269 From $307, Maintains Buy Rating
October 15, 2026  |  marketscreener.comM
Ascendis Pharma A/S $ASND Shares Newly Purchased by Avior Wealth Management LLC
October 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ascendis-pharma-as-asnd-shares-newly-purchased-by-avior-wealth-management-llc-2026-10-15/
Ascendis Pharma A/S (NASDAQ:ASND) Stock Moved Up to "Buy" by Wall Street Zen
October 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ascendis-pharma-as-nasdaq-asnd-stock-moved-up-to-buy-by-wall-street-zen-2026-10-10/
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
October 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3002048/fda-grants-priority-review-to-bridgebio-s-dwarfism-drug-filing?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3002048
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375624/0/en/ascendis-to-share-latest-advances-in-hypoparathyroidism-and-achondroplasia-programs-at-asbmr-2026.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$19.74 +0.01 (+0.05%)
Closing price 04:00 PM Eastern
Extended Trading
$19.66 -0.08 (-0.43%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$245.15 +1.78 (+0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$244.13 -1.02 (-0.42%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas